MA: Corporations In Massachusetts
New York, NY (77WABC)-Despite controversy over its effectiveness, the Food and Drug Administration has green-lighted the first treatment for Alzheimer’s patients in two decades.
The surprise decision came after the agency’s independent advisers said the treatment hadn’t been shown to help treat the brain-destroying disease.
The drug, Aducanumab, was developed by Biogen. It is expected to reduce the clinical decline of patients with Alzheimer’s.
The FDA is not required to follow the advice of the agency it relies on to give it independent advice.
FDA approves the first treatment directed at the underlying biology of Alzheimer’s disease, which is expected to reduce the clinical decline of patients with this disease: https://t.co/xEVvn7V2Fi pic.twitter.com/OaADO8DkZB
— U.S. FDA (@US_FDA) June 7, 2021
This is the first and only drug that the FDA has backed to treat the underlying disease, rather than manage symptoms.
